Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Steven Schwartz | M | 77 |
Syracuse University
Brooklyn College
| 8 anni |
| Robert P. Hickey | M | 78 |
SyntheMed, Inc.
 SyntheMed, Inc. Medical SpecialtiesHealth Technology SyntheMed, Inc. engages in the development and commercialization of medical devices for therapeutic applications. It focuses on the development and commercialization of anti-adhesion, drug delivery products and other surgical implants. The company's products and product candidates, which are based on its proprietary, bioresorbable polymer technology, are primarily surgical implants designed to prevent or reduce the formation of adhesions following a broad range of surgical procedures. Its commercialization efforts have been focused on its lead product, REPEL-CV Bioresorbable Adhesion Barrier, for use in cardiac surgery. The company has changed its name from Life Medical Sciences, Inc. to SyntheMed, Inc. in May 2005. It was founded in August 1990 and is headquartered in Iselin, NJ | 15 anni |
| Shiu Tin Yu | M | 74 |
Syracuse University
| 5 anni |
| C. James Zeszutek | M | - |
Syracuse University
| 7 anni |
| Thomas Herskovits | M | 77 |
Syracuse University
| 6 anni |
| Jules Haimovitz | M | 73 |
Brooklyn College
| 7 anni |
| Joerg Gruber | M | 63 |
SyntheMed, Inc.
SyntheMed, Inc. Medical SpecialtiesHealth Technology SyntheMed, Inc. engages in the development and commercialization of medical devices for therapeutic applications. It focuses on the development and commercialization of anti-adhesion, drug delivery products and other surgical implants. The company's products and product candidates, which are based on its proprietary, bioresorbable polymer technology, are primarily surgical implants designed to prevent or reduce the formation of adhesions following a broad range of surgical procedures. Its commercialization efforts have been focused on its lead product, REPEL-CV Bioresorbable Adhesion Barrier, for use in cardiac surgery. The company has changed its name from Life Medical Sciences, Inc. to SyntheMed, Inc. in May 2005. It was founded in August 1990 and is headquartered in Iselin, NJ | 4 anni |
| Vince Cannaliato | M | - |
Brooklyn College
| 1 anni |
| Sol Waksman | M | - |
Brooklyn College
| 4 anni |
| Robert J. Huljak | M | - |
Syracuse University
| 1 anni |
| Majid Ghafghaichi | M | - |
Brooklyn College
| 4 anni |
| Stephen J. Huber | M | - |
Syracuse University
| 2 anni |
| Yonah Adelman | M | 74 |
Brooklyn College
| 4 anni |
| Stephen Glaudel | M | - |
Syracuse University
| 4 anni |
| Alan Singer | M | - |
Brooklyn College
| 4 anni |
| John S. Hoffer | M | - |
SyntheMed, Inc.
SyntheMed, Inc. Medical SpecialtiesHealth Technology SyntheMed, Inc. engages in the development and commercialization of medical devices for therapeutic applications. It focuses on the development and commercialization of anti-adhesion, drug delivery products and other surgical implants. The company's products and product candidates, which are based on its proprietary, bioresorbable polymer technology, are primarily surgical implants designed to prevent or reduce the formation of adhesions following a broad range of surgical procedures. Its commercialization efforts have been focused on its lead product, REPEL-CV Bioresorbable Adhesion Barrier, for use in cardiac surgery. The company has changed its name from Life Medical Sciences, Inc. to SyntheMed, Inc. in May 2005. It was founded in August 1990 and is headquartered in Iselin, NJ | 6 anni |
| John Benson | M | 62 |
SyntheMed, Inc.
SyntheMed, Inc. Medical SpecialtiesHealth Technology SyntheMed, Inc. engages in the development and commercialization of medical devices for therapeutic applications. It focuses on the development and commercialization of anti-adhesion, drug delivery products and other surgical implants. The company's products and product candidates, which are based on its proprietary, bioresorbable polymer technology, are primarily surgical implants designed to prevent or reduce the formation of adhesions following a broad range of surgical procedures. Its commercialization efforts have been focused on its lead product, REPEL-CV Bioresorbable Adhesion Barrier, for use in cardiac surgery. The company has changed its name from Life Medical Sciences, Inc. to SyntheMed, Inc. in May 2005. It was founded in August 1990 and is headquartered in Iselin, NJ | 5 anni |
| Paul A. Jacobs | M | - |
Brooklyn College
| 4 anni |
| Charles E. Hord | M | - |
Syracuse University
| 3 anni |
| Corinne Mundin | F | - |
SyntheMed, Inc.
SyntheMed, Inc. Medical SpecialtiesHealth Technology SyntheMed, Inc. engages in the development and commercialization of medical devices for therapeutic applications. It focuses on the development and commercialization of anti-adhesion, drug delivery products and other surgical implants. The company's products and product candidates, which are based on its proprietary, bioresorbable polymer technology, are primarily surgical implants designed to prevent or reduce the formation of adhesions following a broad range of surgical procedures. Its commercialization efforts have been focused on its lead product, REPEL-CV Bioresorbable Adhesion Barrier, for use in cardiac surgery. The company has changed its name from Life Medical Sciences, Inc. to SyntheMed, Inc. in May 2005. It was founded in August 1990 and is headquartered in Iselin, NJ | 3 anni |
| Harvey Pitt | M | 79 |
Brooklyn College
| 4 anni |
| Brian Cohen | M | - |
Syracuse University
| 4 anni |
| Alan B. Moldawer | M | - |
Syracuse University
| 4 anni |
| Debi Tappe | F | - |
Syracuse University
| 4 anni |
| Richard Mondre | M | - |
Brooklyn College
| 4 anni |
| Karl J. Ege | M | - |
Syracuse University
| 2 anni |
| Albert Hayoun | M | - |
Brooklyn College
| 4 anni |
| Bruce Werber | M | 70 |
Syracuse University
| 4 anni |
| Martin Schmidt | M | 76 |
Brooklyn College
| 4 anni |
| Abdul Azmin bin Abdul Halim | M | 70 |
Syracuse University
| 4 anni |
| Edward Lazar | M | 73 |
Brooklyn College
| 4 anni |
| Ali Kantur | M | - |
Syracuse University
| 1 anni |
| Gary R. Brown | M | - |
Syracuse University
| 4 anni |
| Davut Ökütçü | M | 78 |
Syracuse University
| 1 anni |
| Daniel J. Pastuf | M | - |
Syracuse University
| 4 anni |
| Gonzalo Restrepo López | M | 73 |
Syracuse University
| 4 anni |
| Joel Klein | M | 77 |
Brooklyn College
| 4 anni |
| Jeffrey Stavin | M | - |
Brooklyn College
| 4 anni |
| Peter H. Watson | M | 75 |
Syracuse University
| 4 anni |
| Kevin Kuppel | M | - |
Syracuse University
| 4 anni |
| Saeed Almulla | M | - |
Syracuse University
| 4 anni |
| Edward Kalikow | M | - |
Syracuse University
| 4 anni |
| David C. Hulihee | M | 75 |
Syracuse University
| 4 anni |
| Alan Sislen | M | - |
Syracuse University
| 4 anni |
| David C. Patch | M | - |
Syracuse University
| 4 anni |
| Stephen B. Huttler | M | - |
Syracuse University
| 4 anni |
| Rudy Lutterschmidt | M | 77 |
Syracuse University
| 4 anni |
| Nicholas Donofrio | M | 78 |
Syracuse University
| 4 anni |
| Sol Barer | M | 76 |
Brooklyn College
| 4 anni |
| Hugh Mcbride | M | 87 |
Syracuse University
| 2 anni |
| Harold Lee Brand | M | 73 |
Brooklyn College
| 8 anni |
| Matthew Dollinger | M | - |
Brooklyn College
| 3 anni |
| Kathleen Walters | F | 72 |
Syracuse University
| 4 anni |
| Rozalie Schachter | M | 78 |
Brooklyn College
| 4 anni |
| Kenneth Andrew Shewer | M | 71 |
Syracuse University
| 4 anni |
| Stewart H. Wahrsager | M | - |
Brooklyn College
| 4 anni |
| Valgene Dunham | M | 82 |
Syracuse University
| 3 anni |
| Marc R. Sportsman | M | 69 |
SyntheMed, Inc.
SyntheMed, Inc. Medical SpecialtiesHealth Technology SyntheMed, Inc. engages in the development and commercialization of medical devices for therapeutic applications. It focuses on the development and commercialization of anti-adhesion, drug delivery products and other surgical implants. The company's products and product candidates, which are based on its proprietary, bioresorbable polymer technology, are primarily surgical implants designed to prevent or reduce the formation of adhesions following a broad range of surgical procedures. Its commercialization efforts have been focused on its lead product, REPEL-CV Bioresorbable Adhesion Barrier, for use in cardiac surgery. The company has changed its name from Life Medical Sciences, Inc. to SyntheMed, Inc. in May 2005. It was founded in August 1990 and is headquartered in Iselin, NJ | 2 anni |
| Mark L. Haley | M | - |
Syracuse University
| 3 anni |
| Jere Northrop | M | 82 |
Syracuse University
| 3 anni |
| Barry Frankel | M | 73 |
SyntheMed, Inc.
SyntheMed, Inc. Medical SpecialtiesHealth Technology SyntheMed, Inc. engages in the development and commercialization of medical devices for therapeutic applications. It focuses on the development and commercialization of anti-adhesion, drug delivery products and other surgical implants. The company's products and product candidates, which are based on its proprietary, bioresorbable polymer technology, are primarily surgical implants designed to prevent or reduce the formation of adhesions following a broad range of surgical procedures. Its commercialization efforts have been focused on its lead product, REPEL-CV Bioresorbable Adhesion Barrier, for use in cardiac surgery. The company has changed its name from Life Medical Sciences, Inc. to SyntheMed, Inc. in May 2005. It was founded in August 1990 and is headquartered in Iselin, NJ | 8 anni |
| Bruce Williams | M | 69 |
Syracuse University
| 4 anni |
| Samuel Herschkowitz | M | 74 |
Syracuse University
| 4 anni |
| David P. Vieau | M | 73 |
Syracuse University
| 4 anni |
| Robert Fagenson | M | 75 |
Syracuse University
| 4 anni |
| Philip Alan Cooper | M | 73 |
Syracuse University
| 4 anni |
| Sheldon M. Schenkler | M | - |
Syracuse University
| 4 anni |
| Barry Hertz | M | 74 |
Brooklyn College
| 4 anni |
| Phyllis G. Korff | F | - |
Brooklyn College
| - |
| Carol Wenom | F | - |
Syracuse University
| 4 anni |
| J. Douglas Robinson | M | - |
Syracuse University
| 1 anni |
| Michael Stafford | M | - |
Brooklyn College
| 4 anni |
| Molly Corbett Broad | F | - |
Syracuse University
| 14 anni |
| Samuel I. Schwartz | M | 70 |
Brooklyn College
| 4 anni |
| James Bertonis | M | - |
Syracuse University
| 4 anni |
| Michael S. Perlis | M | 71 |
Syracuse University
| 4 anni |
| James Lee | M | - |
Syracuse University
| 1 anni |
| Andrea A. Bernstein | F | - |
Syracuse University
| 4 anni |
| David M. Walke | M | 69 |
Syracuse University
| 4 anni |
| Laurence L. Osterwise | M | - |
Syracuse University
| 1 anni |
| Walter R. Maupay | M | 84 |
SyntheMed, Inc.
SyntheMed, Inc. Medical SpecialtiesHealth Technology SyntheMed, Inc. engages in the development and commercialization of medical devices for therapeutic applications. It focuses on the development and commercialization of anti-adhesion, drug delivery products and other surgical implants. The company's products and product candidates, which are based on its proprietary, bioresorbable polymer technology, are primarily surgical implants designed to prevent or reduce the formation of adhesions following a broad range of surgical procedures. Its commercialization efforts have been focused on its lead product, REPEL-CV Bioresorbable Adhesion Barrier, for use in cardiac surgery. The company has changed its name from Life Medical Sciences, Inc. to SyntheMed, Inc. in May 2005. It was founded in August 1990 and is headquartered in Iselin, NJ | 15 anni |
| Frank Tworecke | M | 77 |
Syracuse University
| 2 anni |
| David Allan | M | 82 |
SyntheMed, Inc.
SyntheMed, Inc. Medical SpecialtiesHealth Technology SyntheMed, Inc. engages in the development and commercialization of medical devices for therapeutic applications. It focuses on the development and commercialization of anti-adhesion, drug delivery products and other surgical implants. The company's products and product candidates, which are based on its proprietary, bioresorbable polymer technology, are primarily surgical implants designed to prevent or reduce the formation of adhesions following a broad range of surgical procedures. Its commercialization efforts have been focused on its lead product, REPEL-CV Bioresorbable Adhesion Barrier, for use in cardiac surgery. The company has changed its name from Life Medical Sciences, Inc. to SyntheMed, Inc. in May 2005. It was founded in August 1990 and is headquartered in Iselin, NJ | 8 anni |
| Mark Andrew Fernandez | M | - |
Syracuse University
| 4 anni |
| Barry Turkanis | M | 70 |
Syracuse University
| 4 anni |
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Stati Uniti | 85 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Eli Pines
- Contatti personali
